1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Gufic Biosciences Limited

Gufic Biosciences Limited

GUFICBIO.BO
Gufic Biosciences LimitedIN flagBombay Stock Exchange
396.90
INR
+6.20
- -
40.02BMarket Cap

Total Valuation

Gufic Biosciences Limited carries a market capitalization of 40.02B, placing it among publicly traded companies globally. Its enterprise value stands at 30.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap40.02B
Enterprise Value30.83B

Share Statistics

Gufic Biosciences Limited currently has 100.28M shares outstanding.

Shares Outstanding100.28M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Gufic Biosciences Limited trades at a trailing price-to-earnings ratio of 42.90. The price-to-sales ratio is 2.92, and the price-to-book ratio stands at 274.68.

PE Ratio42.90
PS Ratio2.92
PB Ratio274.68
P/TBV Ratio4.18
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Gufic Biosciences Limited trades at an EV/EBITDA multiple of 25.59 and an EV/FCF ratio of 113.50. The EV/Sales ratio of 3.27 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 25.59 provides insight into valuation relative to core operating earnings.

EV / Sales3.27
EV / EBITDA25.59
EV / EBIT25.59
EV / FCF113.50

Financial Position

Gufic Biosciences Limited maintains a current ratio of 1.55, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 60.87, indicating elevated leverage, while an interest coverage ratio of 3.29 demonstrates adequate ability to service its debt obligations.

Current Ratio1.55
Quick Ratio0.15
Debt / Equity60.87
Debt / EBITDA3.36
Interest Coverage3.29

Financial Efficiency

Gufic Biosciences Limited posts a return on equity of 29.12 and a return on invested capital of 8.93.

Return on Equity (ROE)29.12
Return on Assets (ROA)5.11
Return on Invested Capital (ROIC)8.93
Return on Capital Employed (ROCE)15.46
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.56

Taxes

Over the trailing twelve months, Gufic Biosciences Limited has paid 223.36M in income taxes, reflecting an effective tax rate of 25.81.

Income Tax223.36M
Effective Tax Rate25.81

Stock Price Statistics

Gufic Biosciences Limited's stock has gained approximately 12.34079% over the past 52 weeks. The 50-day moving average sits at 342.68, while the 200-day moving average is 325.51.

Beta (5Y)N/A
52-Week Price Change12.34079%
50-Day Moving Average342.68
200-Day Moving Average325.51
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Gufic Biosciences Limited generated 9.44B in revenue and converted that into 642.14M in net income, yielding earnings per share of 6.40. EBITDA reached 1.21B, while operating income came in at 1.21B.

Revenue9.44B
Gross Profit5.23B
Operating Income1.21B
Pretax Income865.49M
Net Income642.14M
EBITDA1.21B
EBIT1.21B
Earnings Per Share (EPS)6.40

Balance Sheet

Gufic Biosciences Limited holds 762.17M in cash and equivalents against 4.05B in total debt, resulting in a net debt position of 3.23B. Total book value stands at 100.28M, with working capital of 2.84B providing operational flexibility.

Cash & Cash Equivalents762.17M
Total Debt4.05B
Net Debt3.23B
Equity (Book Value)100.28M
Book Value Per Share1.00
Working Capital2.84B

Margins

Gufic Biosciences Limited operates with a gross margin of 55.38, reflecting its pricing power and cost economics. The operating margin of 12.77 and net profit margin of 6.80 provide insight into operational efficiency.

Gross Margin55.38
Operating Margin12.77
Pretax Margin9.17
Profit Margin6.80
EBITDA Margin12.77

Stock Splits

Gufic Biosciences Limited's most recent stock split took place on October 29, 2002 with a 1:10 split ratio.

Last Split Date10/29/2002
Split Ratio1:10

Scores

Gufic Biosciences Limited posts an Altman Z-Score of 3.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.70